Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. (Q50421625)

http://europepmc.org/abstract/MED/29487419

13 March 2018

title

Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. (English)

1 reference

http://europepmc.org/abstract/MED/29487419

13 March 2018

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Craig J. Thomas

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Cynthia J Guidos

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Timothy McKinnon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marielle Yohe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sivasish Sindiri

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Berkley E Gryder

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Jack F Shern

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Leah Kabaroff

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Brendan Dickson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Krista Schleicher

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Guillaume Chouinard-Pelletier

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Serena Menezes

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Abha Gupta

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Xiaohu Zhang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Rajarashi Guha

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marc Ferrer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Yuhong Wei

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Dariush Davani

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Javed Khan

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Rebecca A Gladdy

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

28 February 2018

1 reference

http://europepmc.org/abstract/MED/29487419

13 March 2018

published in

Oncogene

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

2630-2644

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29487419%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/s41388-017-0122-y

5 June 2020

exact match

0 references

cites work

Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Developmental origins of fusion-negative rhabdomyosarcomas.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

PAX3-FOXO1 fusion gene in rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Lineage of origin in rhabdomyosarcoma informs pharmacological response

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiation

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

PI3K and cancer: lessons, challenges and opportunities

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Clonality and evolutionary history of rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Embryonic myogenesis pathways in muscle regeneration

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

A versatile viral system for expression and depletion of proteins in mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Cross-species genomics matches driver mutations and cell compartments to model ependymoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41388-017-0122-Y

7 January 2021

The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29487419

12 December 2020

inferred from PubMed ID database lookup

FGFR4 signaling is a necessary step in limb muscle differentiation.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29487419

12 December 2020

inferred from PubMed ID database lookup

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29487419

12 December 2020